Tag: DMPI

Blue Horseshoe Stocks: DMPI Recap & More

Del Mar Pharmaceuticals, Inc . DMPI

We wanted to swing back around to recap the solid performance of DMPI since we tagged it the day after the Christmas break a couple of weeks back.

It was just a couple sessions later that the stock would find support at .96, and begin a pretty substantial run up the chart. It was helped along by the last six consecutive sessions registering higher base levels of support as the stock has crept all the way up to a high of 1.75, recorded on Friday.

That worked out to a move of 82% in less than two trading weeks, while volume over the same period has been heightened. The high coincided with the current 200DMA, so we’ll look for DMPI to possibly crack that 1.75 mark and head for blue skies.


Kohls Corp KSS

We want to include an options idea for Kohls as we kick off the first full trading week of 2018, on the heels of a solid earnings report.

The company posted strong sales for the holiday season, while giving a significant boost to full year guidance. Shares jumped accordingly in premarket trading, and we are going to be waiting with some targeted weekly contracts to coincide with the activity. We’re going to signal and track the KSS Weekly $58-60 Calls.

Extended Watchlist:
STX, UEPS, ARGS, SDRL, VRAY, NTEC, IMNP, KBSF

Blue Horseshoe Stocks: Kicking Off the Short Week

INSYS Therapeutics, Inc. INSY

This morning we kick off the holiday shortened week, during a time of year that typically sees subdued activity for the markets as a whole, as people spend time with their families, and stay busy with holiday festivities.

We still strive to identify possible opportunities even in this environment, and the first thing to hit our scanner this morning was INSY. INSYS Therapeutics recently initiated Phase II trials of its synthetic Cannabidiol (CBD) Oral Solution for Treatment of Refractory Childhood Absence Epilepsy.

The FDA, we’re learning today, has also granted Fast Track status to INSY for the ‘drug’ for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder. (View PR)

The stock registered its 52-week lows at the beginning of last month, and has been in a general uptrend since, but we’ll be looking for further bullish activity on the heels of this FDA news, both on the stock chart, and in the options chain as a secondary idea. For that, we’ll look to the INSY 01/19 $8 & $9 Calls for opportunities.

DelMar Pharmaceuticals, Inc. DMPI

Speaking of FDA Fast Track designations, we’re looking to DMPI this morning as well, which was granted the status by the FDA for its lead-product cancer treatment, VAL-083.

The chart itself was already set up as a possible bottom play, and despite gapping up considerably on this morning’s news, there is still room to the upside, including a sizable gap that’s been left on the chart since this past spring, the eventual filling of which would spell gains of more than 100% from the current PPS.

Extended Watchlist:
KLXI, EXXI, AEZS, SRAX, IMUC, NETE

Blue Horseshoe Stocks: Fresh Options Plays & More

Options Roundup

Yesterday, we took the opportunity to update readers on the performances of some successful stock calls we made recently. Today we want to turn back to the options trading front with a couple updates on longer-term calls we’ve made, as well as a fresh idea. 

Chipotle Mexican Grill, Inc. CMG – Beginning with the new idea, we we’re noticing a good chart setup on Chipotle, with a number of factors pointing to potential bullish activity forthcoming.  We’d like to signal a range of contracts to watch accordingly. We’ll have our eye on the CMG Weekly $297.50-305 Calls.
________

Verizon Communications, Inc. VZ –  We highlighted a range of calls in the Verizon chain a couple of Fridays ago, and the stock has been on an impressive uptrend ever since. We want to provide updated figures, on the total possible gains we’ve witnessed since putting the VZ 01/19 $45-48 Calls on watch.

$45 Calls – Range: 1.08 -3.95 – Max Gain: 266%
$46 Calls – Range: .59-3.06 – Max Gain: 419%
$47 Calls – Range: .39-2.25 – Max Gain: 477%
$48 Calls – Range: .23-1.55 – Max Gain: 574%

_________

AT&T, Inc. ATT –  We also recently signaled a range of  ATT calls (Nov 9th) on a longer term basis, the ATT 01/19 $34-36 Calls, and those ranges have increased as well, with a bullish performance from T continuing over the past few weeks.

$34 Calls – Range: .91-1.81 – Max Gain: 99%
$35 Calls – Range: .53-1.12 – Max Gain: 111%
$36 Calls – Range: 37-.66 – Max Gain: 78%

Extended Watchlist:

SINO, DPW, RAD, DMPI, GROW, PZRX,